Neurotargeting Group members
Students in the group
Mar Trinidad Fernandez (Feb 2023 – present)
Explore the selective but indirect inhibition of NaV1.7, via regulation of CRMP2 using small-molecule compounds, aiming for a new therapeutic approach for chronic pain. For this, I will be following Lisa Reinmuth's research.
Sarah Weber (Sep 2022 – Dec 2022)
Sofie Breisnes Wormdahl (Aug 2022 – present)
Investigate possible changes in the interaction between tyrosine hydroxylase and 14-3-3 in response to hyperoxia and simulated diving.
Aiza Ashfaq (Aug 2022 – present)
José Miguel Godoy Muñoz (Aug 2022 – present)
Nanobody-aided structural study of activity-regulated cytoskeleton-associated protein (Arc), a multifunctional regulator of synaptic plasticity.
Lasse Neset (May 2022 – present)
Structural and functional studies of activity-regulated cytoskeleton-associated (Arc) protein, using high-affinity nanobodies.
Lucia Wagner (Sep 2021 – Jun 2022)
Investigating the effects of electroconvulsive therapy on the brain's motor coordination and the blood-brain barrier.
Tone Hestad Valland (Sep 2021 – Jun 2022)
She tests different unique natural compounds to see if they can be new drug candidates based on the interaction with the protein Annexin A2.
Elma Cerimagic (Sep 2021 – Jun 2022)
She will be looking at eight different natural compounds to see how they affect cell viability, wound healing and the expression of annexin A2 in PC12 cells.
Inger-Lise Fleisje (Sep 2021 – Jun 2022)
Marcel Schröder (Sep 2021 – Feb 2022)
Biochemical and structural characterization of an interaction between an ultra-high affinity camelid nanobody and an abundant myelin enzyme of the central nervous system.
José Miguel Godoy Muñoz (Aug 2021 – Oct 2021)
Planning, execution, and analysis of routine experiments related to the production and characterisation of recombinant myelin proteins (quality assessments, binding assays, structural determinations).